[Clinical study on the using methods of cisplatin in lung cancer chemotherapy].
BACKGROUND
To compare the therapeutic effectiveness and toxicity between 1-day perfusion and 3-day perfusion of high-dose cisplatin combined chemotherapy for lung cancer.


METHODS
Sixty-four cases of pathologically proved lung cancer were randomized into groups A and B. Group A (32 cases) received cisplatin at d1, and group B (32 cases) received cisplatin at d1-3. Total dosages of cisplatin were same for both groups (100 mg/m²).


RESULTS
Delayed vomiting in group B (40.63%) was significantly lower than that of group A (53.13%) (P<0.05); the early nephrotoxicity rate of group B(25.00%) was lower than that of group A (46.88%), but there was no statistically significant difference between two groups (P>0.05). The therapeutical response was 62.50% in group A, and 68.75% in group B. No significant difference of the chemotherapeutical response was observed between the two groups (P>0.05).


CONCLUSIONS
In the combined chemotherapy of lung cancer, the division administration of high-dose cisplatin can not only guarantee the therapeutic response, but also abate the gastrotoxicity and the nephrotoxicity of cisplatin.
The Department of Medical Oncology, Cancer Center, The First University Hospital, West China University of Medical Sciences, Chengdu, Sichuan 610041, P.R.China.
L
L
Ren
M
M
Hou
D
D
Luo
H
H
Chen
J
J
He